Truist Securities Initiates Coverage On Cyclerion Therapeutics with Buy Rating, Announces Price Target of $14
Truist Securities initiates coverage on Cyclerion Therapeutics (NASDAQ:CYCN) with a Buy rating and announces Price Target of $14.
Cyclerion Therapeutics Highlights Publication Of Preclinical Data Showing Reduction In Neuroinflammation By Brain-Penetrant Soluble Guanlyate Cyclase Stimulator
Cyclerion Therapeutics, Inc. (NASDAQ:CYCN), a clinical-stage biopharmaceutical company developing treatments that restore cognitive function, today announced a publication demonstrating that administration of a small
75 Biggest Movers From Friday
Gainers
The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global Management for $9 per share in all-cash transaction.
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Why Cyclerion Therapeutics Shares Are Moving Today
Cyclerion Therapeutics Inc (NASDAQ: CYCN) shares are trading higher Friday morning after the company announced it will present a trial design for its CY6463 Phase 2a study in patients with Alzheimer's disease with vascular pathology at the at the upcoming Alzheimer's Association International Confer
The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
32 Stocks Moving in Friday’s Pre-Market Session
Gainers
Socket Mobile Inc (NASDAQ: SCKT) shares rose 100.2% to $11.61 in pre-market trading after the company reported better-than-expected Q2 results.